Applying this system to the GBM paradigm, the researchers successfully identified and distinguished signals from single EVs derived from non-cancerous glial cells, various glioma cell lines, and glioma stem cells, including those exhibiting critical molecular alterations such as EGFRvIII oncogenic mutations and MGMT expression. This evidence concerns the gene MGMT and central nervous system cancer.